Author

Masashi Fujii

Observed name: M. Fujii

Institution: Japan Clinical Cancer Research Organization

Observed institutions: Nihon University, Japan Clinical Cancer Research Organization

ORCID: 0000-0001-6707-6040

Observed ORCID: 0000-0001-6707-6040

OpenAlex ID: A5102938337

In vitro production of human antibodies specifically reactive with human gastric cancer cells of established lines and autologous tissues

1987 · Tadatoshi Takayama, Takashi Sakabe, et al. · Journal of Surgical Oncology · 8

The BEETS (JACCRO CC-18) Trial: An Observational and Translational Study of BRAF -Mutated Metastatic Colorectal Cancer

2023 · Chiaki Inagaki, Ryo Matoba, et al. · Future Oncology · 3

Real-world outcomes of encorafenib, cetuximab ± binimetinib for BRAF ‑mutated metastatic colorectal cancer: the BEETS (JACCRO CC‑18) study

2026 · Daisuke Kotani, Eisuke Inoue, et al. · The Oncologist · 2

Study protocol of the C-SOLVE (JACCRO GC-12) trial; a randomized, non-comparative phase II trial of CapeOX or SOX plus zolbetuximab in HER2-negative, CLDN18.2-positive unresectable advanced gastric or esophagogastric junction cancer

2026 · Satoshi Yuki, Hisato Kawakami, et al. · BMC Cancer · 1

PDF

Safety run-in results from C-SOLVE (JACCRO GC-12): A randomized, non-comparative phase II trial of CapeOX or SOX plus zolbetuximab in patients with HER2-negative, CLDN18.2-positive unresectable advanced gastric or GEJ cancer.

2026 · Hisato Kawakami, Satoshi Yuki, et al. · Journal of Clinical Oncology · 1

PDF

Final analysis of modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab for RAS wild-type and left-sided metastatic colorectal cancer: The DEEPER trial (JACCRO CC-13).

2025 · Akihito Tsuji, Yu Sunakawa, et al. · Journal of Clinical Oncology · 1

PDF

Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial

2026 · Yu Sunakawa, Manabu Shiozawa, et al. · Journal of Clinical Oncology

PDF

Individualized estimation of benefit from adjuvant docetaxel plus S-1 in stage III gastric cancer using deep learning–based counterfactual survival analysis of the START-2 trial.

2026 · Hiroki Sato, Wataru Ichikawa, et al. · Journal of Clinical Oncology

PDF

Plasma Biomarkers Associated with Clinical Outcomes of FOLFIRI Plus Ramucirumab in RAS Wild-Type Metastatic Colorectal Cancer: The JACCRO CC-16AR Trial

2026 · Yu Sunakawa, Hisateru Yasui, et al. · Targeted Oncology

Encorafenib and cetuximab with/without binimetinib therapies for patients with BRAF -mutated metastatic colorectal cancer with prognostic factors: The BEETS trial (JACCRO CC-18).

2025 · Yu Sunakawa, Eisuke Inoue, et al. · Journal of Clinical Oncology

PDF

525P Final analysis of the JACCRO CC-16: Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to anti-EGFR antibody

2024 · K. Sugiyama, H. Yasui, et al. · Annals of Oncology

PDF

Correction: Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study

2024 · Yasuhiro Kodera, Kazuhiro Yoshida, et al. · Gastric Cancer

38P Modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab for right-sided or BRAF mutant metastatic colorectal cancer (mCRC): Subgroup analysis of the DEEPER trial (JACCRO CC-13)

2024 · Y. Sunakawa, M. Shiozawa, et al. · Annals of Oncology

482P Blood-based oxidative phosphorylation-related gene signature and their SNPs as novel prognostic biomarkers for gastric cancer patients treated with nivolumab

2024 · C. Inagaki, R. Matoba, et al. · Annals of Oncology

PDF

1547P SNP discovery based on transcriptome sequencing of whole blood RNA to find predictive biomarkers for nivolumab in gastric cancer

2023 · C. Inagaki, R. Matoba, et al. · Annals of Oncology

PDF

Results of surgical treatment of gastric cancer in elderly

2015 · Mitsugu Kochi, M. Fujii, et al. · 日本胃癌学会総会記事

Works count: 16

Citation count: 16

H-index: 2

I10-index: